Advertisement

Hämatopoetische Wachstumsfaktoren (HGF) und Blutprodukte

  • C. Bokemeyer
  • W. Brugger
  • R. Waldmann
  • D. Wernet
Chapter
  • 20 Downloads

Zusammenfassung

Alle peripheren Blutzellen stammen von sog. pluripotenten hämatopoetischen Stammzellen des Knochenmarks ab. Über verschiedene Ausreifungsstufen entstehen Erythrozyten, Thrombozyten, Granulozyten, Monozyten und Lymphozyten. Die Bildung dieser einzelnen Zelltypen und ihre Ausreifung wird über verschiedene hämatopoetische Wachstumsfaktoren reguliert (Abb. 1–1). Einige dieser Wachstumsfaktoren sind mittlerweile biologisch genau charakterisiert und können gentechnologisch, d. h. rekombinant, hergestellt werden. Dies trifft insbesondere für die Wachstumsfaktoren der Myelopoese zu. Innerhalb der Leukozyten spielen die neutrophilen Granulozyten eine entscheidende Rolle bei der körpereigenen unspezifischen Immunabwehr gegenüber Infektionserregern. Zytostatika, Strahlentherapie und immunsuppressive Medikamente beeinträchtigen die Funktion dieser Abwehrzellen, woraus klinisch eine erhöhte Infektanfälligkeit während der Phase der Granulozytopenie — beispielsweise nach einer Chemotherapie — resultiert. Gegenwärtig stehen zwei unterschiedliche hämatopoetische Wachstumsfaktoren (HGF) zur Behandlung bzw. Prävention der chemotherapieinduzierten Granulozytopenie zur Verfügung: granulozyten-koloniestimulierender Faktor (G-CSF) und Granulozyten-Monozyten-Kolonie-stimulierender Faktor (GM-CSF). Beide Faktoren fördern die Proliferation und Differenzierung von Vörläuferzellen der Granulopoese bzw. der Granulo- und Monozytopoese.

Abb. 1–1.

Angriffspunkte verschiedner regulativer Zytokine innerhalb der Organisation und Hierarchie der Hämatopoese

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur zu 1.1

  1. American Society of Clinical Oncology (1996) Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence -based clinical practice guidelines. J Clin Oncol 14: 1957–1960Google Scholar
  2. American Society of Clinicial Oncology (1994) Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 12: 2471–2508Google Scholar
  3. Bokemeyer C, Kuczyk MA, Köhne H, Einsele H, Kynast B, Schmoll HJ (1996) Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy. Ann Hematol 72: 1–9PubMedCrossRefGoogle Scholar
  4. Brodsky RA, Bedi A, Jones RJ (1996) Are growth factors leukemogenic? Leukemia 10: 175–177PubMedGoogle Scholar
  5. Croockewit AJ, Koopmans PP, Pauw BE de (1996) Should hematopoietic growth factors routinely be given concurrently with cytotoxic chemotherapy? Clin Pharmacol Ther 59: 1–6PubMedCrossRefGoogle Scholar
  6. DeLaPena L, Woolery-Antill M, Tomaszewski JG et al. (1996) Hematopoietic growth factors. Cancer Nurs 19: 135–150PubMedCrossRefGoogle Scholar
  7. Demirer T, Buckner CD, Bensinger WI (1996) Optimization of peripheral blood stem cell mobilization. Stem Cells 14: 106–116PubMedCrossRefGoogle Scholar
  8. Ganser A, Karthaus M (1996) Stellung der hämatopoietischen Wachstumsfaktoren in der Onkologie. Educationals, 22. Deutscher Krebskongreß, S 37–39Google Scholar
  9. Hartmann LC, Tschetter LK, Habermann TM et al. (1997) Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 336: 1776–1780PubMedCrossRefGoogle Scholar
  10. Kaushansky K (1996) The thrombocytopenia of cancer. Prospects for effective cytokine therapy. Hematol Oncol Clin North Am 10: 431–455PubMedCrossRefGoogle Scholar
  11. Link H (1996) Therapie mit hämatopoetischen Wachstumsfaktoren G-CSF und GM-CSE In: Schmoll H-J (Hrsg) Kompendium Internistische Onkologie. Springer, Berlin Heidelberg New York Tokio, S 1096–1117Google Scholar
  12. Link H, Herrmann F, Weite K et al. (1994) Rationale Therapie mit G-CSF und GM-CSF. Med Klin 89: 429–439Google Scholar
  13. Marty M (1994) The optimal dose of glycosylated recombinant human granulocyte colony stimulating factor for use in clinical practice: a review. Eur J Cancer 30 A (Suppl 3): 20–25Google Scholar
  14. Morstyn G, Foote M, Lieschke GJ (1996) Hematopoietic growth factors in cancer chemotherapy. Cancer Chemother Biol Resp Mod 16: 295–314Google Scholar
  15. Pitler LR (1996) Hematopoietic growth factors in clinical practice. Semin Oncol Nurs 12: 115–29PubMedCrossRefGoogle Scholar
  16. Uyl-de-Groot CA, Vellenga E, Rutten FF (1996) An economic model to assess the savings from a clinical application of haematopoietic growth factors. Eur J Cancer 32 A: 57–62CrossRefGoogle Scholar
  17. Vogel W, Behringer D, Scheding S, Kanz L, Brugger W (1996) Ex vivo expansion of CD34+ peripheral blood progenitor cells: implications for the expansion of contaminating epithelial tumor cells. Blood 88: 2707–2713PubMedGoogle Scholar
  18. Vose JM, Armitage JO (1996) Clinical application of hematopoietic growth factors. J Clin Oncol 13: 1023–1035Google Scholar

Literatur zu 1.2

  1. Beguin Y (1996) Erythropoietin and the anemia of cancer. Acta Clin Belg 51: 36–52PubMedGoogle Scholar
  2. Bolonaki I, Stiakaki E, Lydaki E, Dimitriou H, Kambourakis A, Kalmantis T, Kalmanti M (1996) Treatment with recombinant human erythropoietin in children with malignancies. Pediatr Hematol Oncol 13: 111–121PubMedCrossRefGoogle Scholar
  3. Cascinu St, Catalano G, Cellerino R (1995) Recombinant human erythropoietin in chemotherapy-associated anemia. Cancer Treat Rev 21: 553–564CrossRefGoogle Scholar
  4. Cazzola M, Messinger D, Battistel V et al. (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response. Blood 86: 4446–4453PubMedGoogle Scholar
  5. Davies SV, Fegan CD, Kendall R, Beguin Y, Cavill I (1995) Serum erythropoietin during autologous bone marrow transplantation: relationship to measures of erytthroid actifity. Clin Lab Haematol 17: 139–144PubMedGoogle Scholar
  6. Dunphy FR, Dunleavy TL, Harrison BR et al. (1997) Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Cancer 79: 1623–1628PubMedCrossRefGoogle Scholar
  7. Eguchi K (1995) Management of chemotherapy-induced anemia. Current Opinion in Oncology 7: 316–319PubMedCrossRefGoogle Scholar
  8. Erslev AJ (1991) Erythropoietin. N Engl J Med 324: 1339–1344PubMedCrossRefGoogle Scholar
  9. Glaspy J, Bukowski R, Steinberg D et al. (1997) Impact of therapy with Epoetin Alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15: 1218–1234PubMedGoogle Scholar
  10. Goodnough LT, Monk TG, Andriole GL (1997) Erythropoietin therapy. N Engl J Med 336: 933–938PubMedCrossRefGoogle Scholar
  11. Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H (1994) Quality of life in chronic anemia of cancer during treatment with recombinant human erythropietin. Cancer 73: 2535–2542PubMedCrossRefGoogle Scholar
  12. Ludwig H, Fritz E (1996) Incidence and clinical significance of anemia in malignant diseases. In: Smyth JF, Boogaerets MA, Ehmer BR-M (eds) Rh-erythropoietin in cancer supportive treatment. Marcel Dekker, New York, pp 35–44Google Scholar
  13. Ludwig H, Fritz E (1996) Pathogenese und Therapie der therapie — und tumorbedingten Anämie. In: Schmoll H-J (Hrsg) Kompendium der Internistischen Onkologie. Springer, Berlin Heidelberg New York Tokio, S 1118–1126Google Scholar
  14. Ludwig H, Sundal E, Pecherstorfer M et al. (1995) Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 76: 2319–2329PubMedCrossRefGoogle Scholar
  15. Messmer K on behalf of the Roundtable of Experts in Surgery Blood Management (1996) Consensus statement: using epoetin alfa to decrease the risk of allogeneic blood transfusion in the surgical setting. Semin Hematol 33 (Suppl 2): 78–80Google Scholar
  16. Negrin RS, Stein R, Doherty K et al. (1996) Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 87/10: 4076–4081PubMedGoogle Scholar
  17. Olivieri- A, Offidani M, Cantori I et al. (1995) Addition of erythropoietin to granulocyte colony-stimulating factor after priming chemotherapy enhances hemopoietic progenitor mobilization. Bone Marrow Transplant 16: 765–70PubMedGoogle Scholar
  18. Pierelli L, Menichella G, Scambia G et al. (1994) In vitro and in vivo effects of recombinant human erythropoietin plus recombinant human G-CSF on human haemopoietic progenitor cells. Bone Marrow Transplant 14: 23–30PubMedGoogle Scholar
  19. Pierelli L, Scambia G, Menichella G et al. (1996) The combination of erythropoietin and granulocyte colony-stimulating factor increases the rate of haemopoietic recovery with clinical benefit after peripheral blood progenitor cell transplantation. Br J Haematol 92: 287–294PubMedCrossRefGoogle Scholar
  20. Sheffield RE, Sullivan SD, Saltiel E, Nishimura L (1997) Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 31: 15–22PubMedGoogle Scholar

Literatur zu 1.3

  1. BCSH Blood Transfusion Task Force (1996) Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-vs.-host disease. Transf Med 6: 261–271CrossRefGoogle Scholar
  2. Bowden RA, Slichter SJ, Sayers M et al. (1995) A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86: 3599–3603Google Scholar
  3. Dienstanweisung der Abteilung für Transfusionsmedizin mit Blutbank Tübingen, Hoppe-Seyler-Str. 3, 72076 Tübingen: Vorbereitung und Durchführung von Bluttransfusionen im Klinikum der Universität TübingenGoogle Scholar
  4. Empfehlungen des Europarates und der Weltgesundheitsorganisation zu Blut und BlutzubereitungenGoogle Scholar
  5. Federowicz I, Barrett BB, Andersen JW et al. (1996) Characterization of reactions after transfusion of cellular blood components that are white cell reduced before storage. Transfusion 36: 21–28PubMedCrossRefGoogle Scholar
  6. Klein HG (1992) Wolf in wolf’s clothing: Is it time to raise the bounty on the passenger leukocyte? Blood 80: 1865–1868PubMedGoogle Scholar
  7. Lichtiger B, Surgeon J, Rhorer S (1983) Rh-incompatible platelet transfusion therapy in cancer patients. Vox Sang 45: 139–143PubMedCrossRefGoogle Scholar
  8. Przepiorka D, LeParc GF, Stovall MA, Werch J, Lichtiger B (1996) Use of irradiated blood components: practice parameter. Am J Clin Pathol 106: 6–11PubMedGoogle Scholar
  9. Przepiorka D, LeParc GF, Werch J, Lichtiger B (1996) Prevention of transfusion-associated cytomegalovirus infection. Practice parameter. American Society of Clinical Pathologists. Am J Clin Pathol 106: 163–169PubMedGoogle Scholar
  10. Richtlinien zur Blutgruppenbestimmung und Bluttransfusion, aufgestellt vom wissenschaftlichen Beirat der Bundesärztekammer und vom BundesgesundheitsamtGoogle Scholar
  11. Schnaidt M, Northoff N, Wernet D (1996) Frequency and specificity of platelet-specific alloantibodies in HLA-immunized haematologic- oncologic patients. Transf Med 6: 111–114CrossRefGoogle Scholar
  12. Sprogoe-Jakobsen U, Saetre AM, Georgsen J (1995) Preparation of white cell-reduced red cells by filtration: comparison of a bedside filter and two blood bank filter systems. Transfusion 35: 421–426PubMedCrossRefGoogle Scholar
  13. Van Prooijen HC, Visser JJ, Van Oostendorp WR, Gast GC de, Verdonck LF (1994) Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white blood cells from blood components with high-affinity filters. Br J Haematol 87: 144–147PubMedCrossRefGoogle Scholar
  14. Walter-Coleman S (1996) Transfusion therapy for patients critically ill with cancer. AACN Clin Issues 7: 37–45PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • C. Bokemeyer
  • W. Brugger
  • R. Waldmann
  • D. Wernet

There are no affiliations available

Personalised recommendations